TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
暂无分享,去创建一个
E. Nievergall | J. Reynolds | W. Erber | S. Busfield | G. Vairo | D. White | T. Hughes | C. Kok | D. Yeung | A. Lopez | D. Hiwase | R. Grose | M. Biondo | D. Watkins | T. Sadras | K. Fuller | T. Hughes | D. White | Teresa Sadras | John V. Reynolds | Wendy N. Erber | D. T. Yeung | Chung H. Kok | Dale B. Watkins | Kathy A. Fuller | Angel F. Lopez | Timothy P Hughes